What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant's own immune cells designed to target B7-H3. All eligible participants will receive up to 15 intraventricular administrations of BCB-276 every 2 weeks for an…”In the company’s words, NCT07680439 on ClinicalTrials.gov
- Tested for
- Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood and 4 more
- Main trialPhase 2
- “This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG. To participate, individuals must…”In the company’s words, NCT07680439 on ClinicalTrials.gov
Other drugs for Diffuse Intrinsic Pontine Glioma
- VRT106Guangzhou Virotech Pharmaceutical Co., Ltd. · Phase 2
- OlutasidenibRigel Pharmaceuticals · Forma Therapeutics, Inc. · Phase 2
- LSAM-CisplatinNanOlogy, LLC (doing business as Intryx Therapeutics, LLC) · Phase 1/2
- CobolimabGSK · Phase 1/2
- DostarlimabGSK · Phase 1/2
- CLR 131Cellectar Biosciences, Inc. · Phase 1
Coming up1
- Oct 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2028 | Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026